Cargando…

Utilizing tocilizumab for the treatment of cytokine release syndrome in COVID-19

Detalles Bibliográficos
Autores principales:	Hassoun, Ali, Thottacherry, Elizabeth Dilip, Muklewicz, Justin, Aziz, Qurrat-ul-ain, Edwards, Jonathan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229471/ https://www.ncbi.nlm.nih.gov/pubmed/32425661 http://dx.doi.org/10.1016/j.jcv.2020.104443

Ejemplares similares

256. Optimizing the Clinical Utilization of T2 Rapid Candida Panel at a Large Community Hospital
por: Thottacherry, Elizabeth, et al.
Publicado: (2019)

The effect of tocilizumab on cytokine release syndrome in COVID-19 patients
por: de Cáceres, Carmen, et al.
Publicado: (2020)

Effectiveness of Tocilizumab in a COVID-19 Patient with Cytokine Release Syndrome
por: Uslu, Sadettin
Publicado: (2020)

Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome
por: van Kraaij, Tom DA, et al.
Publicado: (2020)

SAT326 Massive Adrenomyelolipomas Due To Longstanding CAH
por: Aziz, Qurrat-ul-ain, et al.
Publicado: (2023)

Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date
por: Si, Stephanie, et al.
Publicado: (2020)

Tocilizumab Use in COVID-19 Cytokine-release Syndrome: Retrospective Study of Two Centers
por: Nasa, Prashant, et al.
Publicado: (2020)

Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes
por: Price, Christina C., et al.
Publicado: (2020)

Subcutaneous tocilizumab treatment in patients with severe COVID-19–related cytokine release syndrome: An observational cohort study
por: Mastroianni, Antonio, et al.
Publicado: (2020)

2425. Correlating Use of High-Risk Antimicrobials and the Incidence of Hospital-Onset Clostridium difficile Infection: Targeting Prescribing Trends for Antimicrobial Stewardship
por: Thottacherry, Elizabeth, et al.
Publicado: (2019)

Tocilizumab in a child with acute lymphoblastic leukaemia and COVID-19-related cytokine release syndrome()
por: Velasco Puyó, Pablo, et al.
Publicado: (2020)

Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome: A Cautionary Case Report
por: Radbel, Jared, et al.
Publicado: (2020)

Therapeutic Effect of Tocilizumab on Inhibiting Cytokine Release Syndrome in Severe Coronavirus Disease 2019 Patients
por: Xu, Lengnan, et al.
Publicado: (2022)

Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)?
por: Liu, Danfei, et al.
Publicado: (2020)

Tocilizumab and Cytokine Release Syndrome in COVID-19 Pneumonia: Experience From a Single Center in Pakistan
por: Hassan, Muhammad, et al.
Publicado: (2021)

Notes From the Field: The Combined Effects of Tocilizumab and Remdesivir in a Patient With Severe COVID-19 and Cytokine Release Syndrome
por: Ali, Sabahat, et al.
Publicado: (2021)

Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome
por: Sarhan, Neven Mohamed, et al.
Publicado: (2023)

FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell‐Induced Severe or Life‐Threatening Cytokine Release Syndrome
por: Le, Robert Q., et al.
Publicado: (2018)

Effects of Alt-RAMEC protocol with facemask therapy in cleft lip palate patients in a sample of Pakistani population
por: Sami, Qurrat-ul-ain, et al.
Publicado: (2023)

Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19
por: Saha, Abinit, et al.
Publicado: (2020)

Case Study: A Patient with Asthma, Covid-19 Pneumonia and Cytokine Release Syndrome Treated with Corticosteroids and Tocilizumab
por: Schleicher, Gunter K, et al.
Publicado: (2020)

A 20-year single community-based tertiary care center’s experience with cardiac myxomas
por: Velu, Dhivya, et al.
Publicado: (2022)

Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality
por: Zhang, Chi, et al.
Publicado: (2020)

Successful treatment of severe COVID-19 pneumonia and hyperinflammatory syndrome with tocilizumab
por: Gentile, Giorgio, et al.
Publicado: (2021)

Combination therapy of Tocilizumab and steroid for management of COVID-19 associated cytokine release syndrome: A single center experience from Pune, Western India
por: Dravid, Ameet, et al.
Publicado: (2021)

Influence of Cytokine Release Syndrome in Severe COVID-19 Patients Treated With Tocilizumab Over the Quantiferon TB Gold Plus Results
por: Sánchez-Martínez, Francesca, et al.
Publicado: (2021)

Integrative analyses of conserved WNT clusters and their co-operative behaviour in human breast cancer
por: Qurrat-ul-Ain,, et al.
Publicado: (2011)

Plant Alkaloids as Antiplatelet Agent: Drugs of the Future in the Light of Recent Developments
por: Ain, Qurrat-Ul-, et al.
Publicado: (2016)

Role of antimicrobial peptide cathelicidin in thrombosis and thromboinflammation
por: Zhang, Qing, et al.
Publicado: (2023)

Gallbladder wall perforation secondary to empyema in Mirizzi’s syndrome: An unseen complication. A case report
por: Alqahtani, Awadh, et al.
Publicado: (2020)

Multidisciplinary Approach to Improve Utilization and Cost Savings of Multiplex Polymerase chain reaction (PCR) Respiratory Pathogen Testing in a Large Community Hospital
por: Hassoun, Ali, et al.
Publicado: (2017)

Evaluation and Optimization of Prolonged Release Mucoadhesive Tablets of Dexamethasone for Wound Healing: In Vitro–In Vivo Profiling in Healthy Volunteers
por: Javed, Qurrat ul Ain, et al.
Publicado: (2022)

Utilization of the T2 Candida Panel for Rapid Candida Species Detection in a Large Community Hospital
por: Hassoun, Ali, et al.
Publicado: (2017)

3-Amino-N′-(2-oxoindolin-3-ylidene)benzohydrazide
por: Jamal, Rifat Ara, et al.
Publicado: (2011)

Rapid resolution of cytokine release syndrome and favorable clinical course of severe COVID-19 in a kidney transplant recipient treated with tocilizumab
por: Gautier-Vargas, Gabriela, et al.
Publicado: (2020)

Interleukin-6 Antagonist Tocilizumab to Treat Critically Ill Coronavirus Disease 2019 Patients With Cytokine Release Syndrome: A Case Series
por: Yang, Stephen Su, et al.
Publicado: (2021)

Development of genetic tools for heterologous protein expression in a pentose‐utilizing environmental isolate of Pseudomonas putida
por: Gauttam, Rahul, et al.
Publicado: (2023)

P946: TOCILIZUMAB PRE-TREATMENT SIGNIFICANTLY REDUCES THE INCIDENCE OF CYTOKINE RELEASE SYNDROME IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WHO RECEIVE CEVOSTAMAB
por: Mateos, Maria-Victoria, et al.
Publicado: (2023)

Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia?
por: Antinori, Spinello, et al.
Publicado: (2020)

Efficacy of Tocilizumab Therapy in Different Subtypes of COVID-19 Cytokine Storm Syndrome
por: Oliynyk, Oleksandr, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rch3h9v3kd3af2vqg89f407g08